As of today (2024-05-05), the Trailing Annual Dividend Yield of Paratek Pharmaceuticals is 0.00%.
The historical rank and industry rank for Paratek Pharmaceuticals's Dividend Yield % or its related term are showing as below:
During the past 13 years, the highest Dividend Yield of Paratek Pharmaceuticals was 69.99%. The lowest was 21.23%. And the median was 42.09%.
PRTK's Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.49 * Ranked among companies with meaningful Dividend Yield % only.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Paratek Pharmaceuticals's Dividend Yield %
For the Biotechnology subindustry, Paratek Pharmaceuticals's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Paratek Pharmaceuticals's Dividend Yield % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Paratek Pharmaceuticals's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Paratek Pharmaceuticals's Dividend Yield % falls into.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Paratek Pharmaceuticals Dividend Yield % Related Terms
Thank you for viewing the detailed overview of Paratek Pharmaceuticals's Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
Paratek Pharmaceuticals (Paratek Pharmaceuticals) Business Description
Paratek Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's medical research is based on tetracycline chemistry and biology to create two antibacterials: omadacycline and sarecycline. NUZYRA (Omadacycline) is an antibacterial for skin infections and treatment of community-acquired bacterial pneumonia. SEYSARA (Sarecycline) is designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals is also involved in research to treat multiple sclerosis, spinal muscular atrophy, and systemic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel diseases.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PRTK has been successfully added to your 